<DOC>
	<DOCNO>NCT00291473</DOCNO>
	<brief_summary>Mixed cancer vaccine , CHP-HER2 protein CHP-NY-ESO-1 protein , study evaluate safety immune response patient positive either antigen . Nine patient enrol , refractory standard therapy cancer high risk relapse . CHP-HER2 CHP-NY-ESO-1 subcutaneously give bimonthly basis , together OK-432 ( Picibanil ) immunoadjuvant . Six dose give . Toxicity profile monitor , antigen specific humoral anad T cell response describe .</brief_summary>
	<brief_title>Safety Immunogenicity CHP-HER2 CHP-NY-ESO-1 Protein With OK-432 Antigen-Expressing Cancers</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Histological confirmation cancer . 2 . HER2 expression tumor cell score 1+ confirm IHC use least two antibody ( archived issue ; see Appendix 1 Reference 1 methodology ) . NYESO1 expression reverse transcriptase polymerase chain reaction ( RTPCR ) analysis ( Appendix 2 ) , preferably , immunohistochemistry 3 . Patients must 1. high risk recurrence , 25 % probability , complete resection even postoperative adjuvant treatment , effective adjuvant therapy available refuse ; 2. metastatic disease , treatment fail , situation effective therapy available , refuse . 4 . Complete recovery surgery ( least 4 week ) . 5 . Laboratory value within follow limit : Hemoglobin 9.0 g/dL , 10.0 g/dL &lt; 50 kg Neutrophil count &gt; 1.5 x 109/L Lymphocyte count &gt; 0.5 x 109/L Platelet count &gt; 100 x 109/L Serum creatinine ≤ 1.8 mg/dL Serum bilirubin ≤ 2 mg/dL 6 . Performance status &gt; 70 ( Karnofsky Scale ) life expectancy &gt; 3 month . 7 . Age 18 year . 1 . Clinically significant heart disease ( NYHA Class III IV ) . 2 . Cardiac dysfunction ; le 50 % ejection fraction echocardiogram . 3 . Immunodeficiency disease . 4 . Other serious illness , eg , serious infection require antibiotic , bleed disorder . 5 . Previous bone marrow stem cell transplant . 6 . Metastatic disease central nervous system , unless treat stable . 7. known HIV antibody positivity . 8 . Anaphylactic reaction previous vaccination . 9 . Hypersensitivity penicillin 10 . Chemotherapy , type radiation therapy , immunotherapy within 4 week study entry ( 6 week nitrosoureas ) . 11 . Concomitant treatment steroid . Topical inhalational steroid permit . 12 . Participation clinical trial involve another investigational agent within 4 week prior enrollment . 13 . Pregnancy nursing . 14 . Refusal , woman childbearing potential , use medically acceptable mean contraception . 15 . Mental impairment may compromise ability give informed consent . 16 . Lack availability immunological clinical followup assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>